News Details - novonordisk.com
WEBSep 19, 2024 · Wegovy ® (semaglutide 2.4 mg) is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise function in people with obesity-related heart failure with preserved ejection fraction (HFpEF).
News details - Novo Nordisk
WEBMar 8, 2024 · Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity. Wegovy® (semaglutide) injection 2.4 mg is the first-and-only medicine indicated for both reduction of the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke and for long-term ...
News Details - Novo Nordisk
WEBJun 4, 2021 · Wegovy™ is the first and only once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management for people living with obesity. The approval is based on the results from the STEP phase 3a clinical trial programme.
News Details - Novo Nordisk
WEBWegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease. Bagsværd, Denmark, 8 March 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy ® based on a supplemental New Drug Application ...
News details - Novo Nordisk
WEBPLAINSBORO, NJ, December 23, 2022 – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Wegovy ® (semaglutide) injection 2.4 mg, making it the first-and-only prescription anti-obesity medicine for teens with once-weekly dosing.
News details - Novo Nordisk
WEBPLAINSBORO, N.J., June 4, 2021 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Wegovy ™ (semaglutide) injection 2.4 mg, the first-and-only prescription weight-loss medication with once-weekly dosing.
Novo Nordisk hits $500 billion in market value as it flags soaring ...
WEBJan 31, 2024 · Novo Nordisk hits $500 billion in market value as it flags soaring demand for Wegovy, Ozempic. The maker of weight loss drug Wegovy and diabetes drug Ozempic reported an increase in sales of 31% ...
Novo Nordisk Wegovy approved for cutting heart disease risks
WEBMar 8, 2024 · The Food and Drug Administration approved Novo Nordisk’s blockbuster weight loss drug Wegovy for use in slashing the risk of serious cardiovascular complications in people with obesity and heart ...
Novo's Wegovy shows heart benefit alongside weight loss in trial
WEBCOPENHAGEN/LONDON, Aug 8 (Reuters) - Wegovy maker Novo Nordisk (NOVOb.CO) said on Tuesday a large study had shown the highly effective obesity treatment also had a clear cardiovascular...
Novo Nordisk hikes outlook on soaring demand for Wegovy, …
WEBOct 13, 2023 · Soaring demand of Ozempic and Wegovy have led to Novo Nordisk’s meteoric rise. Novo Nordisk on Friday raised its outlook for its full-year sales and operating profit due to soaring demand for ...